and medical innovation. Reliable annual data are available for only one type of innovation - new drugs - but … for the hypothesis that both medical innovation (in the form of new drug approvals) and expenditure on medical care …

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual data are available … for only one type of innovation new drugs but pharmaceutical R&D accounts for a significant fraction of total biomedical … research. The empirical analysis provides strong support for the hypothesis that both medical innovation (in the form of new …

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …